Total: $1,062.94

Company
(Symbol)#
(M)

Type Of
Financing

Number Of
Shares, Units
Or Warrants

Amount
Raised
(M)

Investors; Placement Agents; Details
(Date)@


Adventrx
Pharmaceuticals
Inc.
(AMEX:ANX)

Private placement of stock

14.545S

$40

Accredited and institutional investors purchased the stock at $2.75 per share; ThinkEquity Partners LLC was lead placement agent; Fortis Securities LLC was co-agent (11/3)

Akesis
Pharmaceuticals
Inc.
(OTC BB:AKES)

Private placement of stock and warrants

5.85S and 0.878W

$3.51

The shares were sold at $0.60 each; warrants are exercisable at the same price; $3M of the investment was provided by Avalon Ventures VII LP (11/27)

Anesiva Inc.
(ANSV)

Registered direct offering

7S

$44.8

The registered stock was sold to institutional investors at $6.40 per share, the Nov. 21 closing price; Lazard Capital Markets LLC was lead placement agent; Needham & Co. LLC and Rodman & Renshaw LLC were co-agents (11/22)

Avanir
Pharmaceuticals
Inc.
(AVNR)

Private placement of stock and warrants

5.265S and 1.053W

$15

Institutional investors purcahsed the stock at $2.85 per share; the one-year warrants are exercisable at $3.30 per share; Rodman & Renshaw LLC was placement agent (11/3)

Biofusion plc
(UK; AIM:BFN)

Private placement of stock

5.35S

£7.75 ($15.3)

Shares were sold at 145 pence each in a deal fully underwritten by Nomura Code Securities (11/30)

BioMS
Medical Corp.
(Canada; TSX:MS)

Private placement of stock and warrants

6.129S and 3.065W

C$20.9 ($18.3)

Units consisting of one share and one-half warrant were sold at C$3.41 each; full four-year warrants are exercisable at C$4 per share; Versant Partners Inc. and Rodman & Renshaw were co-lead placement agents; Fondsfinans ASA was co-agent (11/24)

BioTie
Therapies
Oyj
(Finland;
HSE:BTH1V)

Private placement of stock

25.49S

€13 ($17.2)

Investors including Pequot Capital, Dreadnought Finance Oy, Thominvest Oy and SITRA purchased the stock at €0.51 per share; another €7.5M could be added to the deal by retail investors (11/30)

Cangene
Corp.
(Canada;
TSX:CNJ)

Bought-deal financing

4.375S

C$35.4 ($31)

Underwriters led by GMP Securities LP and including TD Securities Inc., Scotia Capital Inc. and Sprott Securities Ltd. purchased the stock at C$8.10 per shares; totals do not include 5.625M shares sold in the deal by existing shareholders (11/21)

Clinuvel
Pharmaceuticals
Ltd.
(Australia;
ASX:CUV)

Rights issue and private placement

91.4S

A$35.2 ($27.1)

Clinuvel raised A$30.5M in a rights issue and A$4.7M in a private placement; shares were sold at A$0.385 in each deal (11/1)

CollaGenex
Pharmaceuticals
Inc.
(CGPI)

Private placement of stock

3.5S

$45.5

Institutional and other investors are purchasing the registered shares at $13 each, a 2% discount to the prior day's close; Lazard Capital Markets LLC was placement agent (11/16)

Corcept
Therapeutics
Inc.
(CORT)

Private placement of stock

3S

$3

Paperboy Ventures LLC led the financing, which included Sutter Hill Ventures and three members of Corcept's board (11/15)

Crucell NV
(the Netherlands;
CRXL)

Private placement of stock

ND

€80 ($105)

The funds were raised as part of Crucell's acquisition of SBL Vaccin AB; specific details on the financing were not disclosed (11/21)

Cytogen
Corp.
(CYTO)

Private placement of stock and warrants

7.09S and 3.546W

$20

Institutional investors purchased units at $2.82 each; the five-year warrants are exercisable at $3.32 per share (11/7)

Discovery
Laboratories
Inc.
(DSCO)

Private placement of stock and warrants

4.6S and 2.3W

$10

One institutional investor purchased the stock at $2.16 per share, a 5% discount to a five-day average; the five-year warrants are exercisable at $3.18 per share; Jefferies & Co. Inc. was placement agent (11/22)

Dyadic
International
Inc.
(AMEX:DIL)

Private placement of stock and warrants

2.787S and 0.557W

$13

The stock was sold at $4.68 per share; the 3.5-year warrants are exercisable, after 180 days, at $6.33 per share; Cowen and Co. LLC was placement agent (11/20)

Hollis-Eden
Pharmaceuticals
Inc.
(HEPH)

Private placement of stock and warrants

4S and 0.8W

$26

The registered shares were sold at $6.50 each; the four-year warrants are exercisable at $8.75 per share; Rodman & Renshaw LLC was lead placement agent; Canaccord Adams Inc. was co-agent (11/8)

Introgen
Therapeutics
Inc.
(INGN)

Private placement of stock

1.32S

$6.1

An institutional investor purchased the registered shares; Mulier Capital was placement agent (11/7)

Lumera
Corp.
(LMRA)

Private placement of stock and warrants

2.825S and 0.424W

$16.95

The shares were sold at $6 each; the five-year war- rants are exercisable at $6.25 per share; the investment was led by Robert W. Baird & Co. (11/8)

Metabasis
Therapeutics Inc.
(MBRX)

Committed equity facility

N/A

N/A

Kingsbridge Capital Ltd. committed to buy up to $50M in Metabasis stock over three years at a dis-count of 6% to 10%; Metabasis will determine the timing and amount of any sale (11/2)

Migenix Inc.
(Canada;
TSX:MGI)

Bought-deal financing

16.75U

C$10 ($8.74)

A Canadian investment dealer purchased the units at C$0.60 per unit; each consists of one common share and one-half of a warrant; each whole war- rant is exercisable at C$0.80 per share (11/16)

Millennium
Pharmaceuticals
Inc.
(MLNM)

Sale of convertible notes

N/A

$250

The 2.25% notes are due in 2011; they are convertible into common shares at an intial price of $15.47 per share; Morgan Stanley & Co. Inc. and JP Morgan Securities Inc. are joint managers for the deal; totals include their purchase of $25M in the notes per an overallotment option (11/9)

Neurochem
Inc.
(Canada;
NRMX)

Private
placement of
convertible
notes

N/A

$42.09

The 6% notes due in 2026 carry a conversion premium of 20%, initially $19.72 per share; totals include the purchase of $2.085M in notes by UBS Securities LLC per its overallotment option (11/3)

Neuro-Hitech
Inc.
(OTC
BB:NHPI)

Private placement of stock and warrants

0.605S and 0.302W

$3.1

Up to 604,878 shares and 302,439 warrants are being sold; the exact number of shares and warrants will equal the greater of $5.125 per share or a 20% discount to a 20-day trading average prior to its acquisition of Q-RNA Inc.; the warrants will be exercisable at $7 per share (11/17)

Nymox
Pharmaceutical
Corp.
(NYMX)

Private
placement of
stock

ND

$13

Institutional investors purchased the shares at a 3% discount to the market price; the number of shares and the price were not disclosed (11/29)

Pipex
Pharmaceuticals
Inc.
(OTC BB:SFPH)

Private placement of stock and warrants

13.7S and 6.8W

$13.7

Accredited Venture Capital LLC provided $4.5M in funding prior to Pipex's merger with Sheffield Pharmaceuticals Inc.; the second deal totaling $9.2M involved the sale of 13.7M shares and 6.8M warrants exercisable at $0.74 per share (11/28)

Prana
Biotechnology
Ltd.
(Australia;
PRAN)

Private
placement of
stock and
warrants

21.8S and 4.35W

A$7.8 ($6.1)

Shares are being purchased at A$0.357 per share (about $2.80 per ADR); the options are exercisable at A$0.446 per share (about $3.40 per ADR) (11/21)

Protox
Therapeutics
Inc.
(Canada;
CDNX:PRX)

Private placement of stock and warrants

18.35S and 9.175W

C$9.17 ($8)

Units consisting of one share and half a warrant were sold at C$0.50 each; each one-year warrant is exercisable at C$0.65 per share; Jennings Capital Inc. and Canaccord Capital Corp. co-led the deal (11/29)

Regeneron
Pharmaceuticals
Inc.
(REGN)

Private placement of stock

7.6S

$175

Morgan Stanley & Co. Inc. purchased the registered shares at $23.03 each (11/13)

SR Pharma pl (UK; AIM:SPA)

Private placement of stock

20S

£3.8 ($7.2)

Institutional investors, including some existing shareholders, purchased the stock at 19 pence per share (11/6)

Tm Bioscience
Corp.
(Canada;
TSX:TMC)

Credit facility

N/A

N/A

Laurus Master Fund Ltd. provided the 7% credit facility, payable initially with stock at C$0.71 per share; the facility matures on Aug. 31, 2007 (11/28)

TopoTarget
A/S
(Denmark;
CSE:TOPO)

Private placement of stock

4.153S

DKK126.7 ($22.5)

The stock was sold at DKK30.5 per share; ABN AMRO Rothschild and Handelsbanken Capital Markets were placement agents (11/28)

Vasogen Inc.
(Canada; VSGN)

Private placement of stock and warrants

43.2S and 21.6W

$20.3

Units consisting of a share and half a warrant were sold at $0.47 each; 80% of the warrants are exercisable for five years at $0.63 per share; 20% are exercisable for six months at $0.53 per share; Rodman & Renshaw LLC was placement agent (11/9)

Virax
Holdings Ltd.
(Australia; ASX:
VHL)

Rights issue and placement

13.5S

A$2.36 ($1.85)

Shareholders subscribed to A$0.56M in stock, and A$1.80 million was committed by way of shortfall placement agreements with Tricom Equities Ltd. (11/9)

Vivus Inc.
(VVUS)

Registered direct offering

9.6S

$33.6

The registered shares were purchased at $3.50 each; Caxton Advantage Life Sciences Fund LP led the financing, which also included Euclid SR Partners, OrbiMed Advisors LLC, Franklin Templeton Investments and Quogue Capital LLC (11/20)


Notes:

This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

Currency conversions are based on exchange rates at the time of the deal.

N/A = Not applicable; ND = Not disclosed.

AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; CSE = Copenhagen Stock Exchange; HSE = Helsinki Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange.

No Comments